Currently Viewing:
The American Journal of Managed Care November 2013
Opioid Analgesic Treated Chronic Pain Patients at Risk for Problematic Use
Joseph Tkacz, MS; Jacqueline Pesa, PhD, MPH; Lien Vo, PharmD, MPH; Peter G. Kardel, MA; Hyong Un, MD; Joseph R. Volpicelli, MD, PhD; and Charles Ruetsch, PhD
Currently Reading
Safety and Effectiveness of Mail Order Pharmacy Use in Diabetes
Julie A. Schmittdiel, PhD; Andrew J. Karter, PhD; Wendy T. Dyer, MS; James Chan, PharmD, PhD; and O. Kenrik Duru, MD, MSHS
Creating Peer Groups for Assessing and Comparing Nursing Home Performance
Margaret M. Byrne, PhD; Christina Daw, PhD; Ken Pietz, PhD; Brian Reis, BE; and Laura A. Petersen, MD, MPH
Upcoding Emergency Admissions for Non-Life-Threatening Injuries to Children
Zachary Pruitt, MHA; and Etienne Pracht, PhD
Variations in the Service Quality of Medical Practices
Dan P. Ly, MD, MPP; and Sherry A. Glied, PhD
Using Health Outcomes to Validate Access Quality Measures
Julia C. Prentice, PhD; Michael L. Davies, MD; and Steven D. Pizer, PhD
Collecting Mortality Data to Drive Real-Time Improvement in Suicide Prevention
Brian K. Ahmedani, PhD; M. Justin Coffey, MD; and C. Edward Coffey, MD

Safety and Effectiveness of Mail Order Pharmacy Use in Diabetes

Julie A. Schmittdiel, PhD; Andrew J. Karter, PhD; Wendy T. Dyer, MS; James Chan, PharmD, PhD; and O. Kenrik Duru, MD, MSHS
Patients using mail order pharmacies have lower healthcare utilization, but somewhat less laboratory monitoring of persistent medications and slightly higher contraindicated medication use.
Mail order pharmacy services, which are provided at the healthcare delivery system level rather than the physician or practice level, can be considered a structural or system-level intervention for improving access to chronic illness medications.3,7 While this study and others3-7 suggest that using mail order pharmacy services may improve outcomes, our study also suggests that certain patients may be more sensitive to any potential negative impact of mail order pharmacy use on healthcare access. System-level efforts to promote mail order use should preserve patient choice in pharmacy services and maintain a patient-centered approach to meeting an individual’s overall healthcare needs. Future research should continue to address the important issue of how to appropriately target and promote mail order pharmacy services while preserving the benefits of in-person interaction with pharmacists and other care providers.

This study has several limitations. Observational studies cannot entirely control for differences between patients who use mail order pharmacy services and those who do not. While our sensitivity analysis demonstrated that the relationship between mail order pharmacy use and our outcomes would still be observed even in the presence of a powerful, prevalent confounder, future research should leverage randomized controlled trial designs to examine the impact of mail order pharmacy use on intermediate outcomes, healthcare utilization, and patient safety.

We were unable to ascertain pharmacy utilization at non-KPNC pharmacies. However, we limited our analyses to members with a drug benefit, which is only recognized at KPNC pharmacies. This under-ascertainment should be minimal, as previous research suggests that diabetes patients with drug benefits report extremely low use of non-KPNC pharmacies.26

This study was conducted in an integrated delivery system where patients access prescription medications differently than in many other settings. Use of “brick and mortar” pharmacies to fill prescriptions is primarily limited to KPNC local pharmacies; KPNC’s mail order and local pharmacies do not differ in the standard days of supply of pills issued; and mail order pharmacy does not require physician enrollment of the prescription. In addition, KPNC local pharmacies are primarily co-located with medical offices and laboratories, which is often not the case in other settings. This co-location may make any relationship between in-person pharmacy use and preventive care services stronger than in cases where patients obtain in-person refills from brick-and-mortar pharmacies that are not integrated with outpatient care. It is therefore possible that the use of mail order pharmacy services in KPNC has a different impact on outcomes than it would have in other settings.

CONCLUSION

Mail order pharmacy use is not associated with adverse events in most diabetes patients and may be associated with improved health outcomes. System-level interventions to increase mail order pharmacy use may be an important strategy for improving processes and outcomes of care for patients with chronic illness; however, these interventions should use a patient-centered approach that does not increase risk in older patients and others who may be sensitive to primary and preventive care access.

Author Affiliations: From Division of Research (JAS, AJK, WTD), Pharmacy Outcomes Research Group (JC), Kaiser Permanente Northern California, Oakland, CA; David Geffen School of Medicine (KD), University of California, Los Angeles; Los Angeles, CA.

Funding: This study was funded by the Division of Diabetes Translation, Centers for Disease Control and Prevention, contract CDC U58 DP002641. This activity was also supported by the Health Delivery Systems Center for Diabetes Translational Research (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK] grant 1P30-DK092924), the Diabetes Study of Northern California (NIDDK grant R01 DK080726), and the Diabetes and Aging Study (NIDDK grant R01 DK0817960); the Harold Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation; and the National Institute on Aging (grant K08 AG033630). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding organizations.

Author Disclosures: The authors (JAS, AJK, WTD, JC, OKD) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Authorship Information: Concept and design (JAS, AJK, OKD); acquisition of data (JAS, AJK, WTD); analysis and interpretation of data (JAS, WTD, JC, OKD); drafting of the manuscript (JAS); critical revision of the manuscript for important intellectual content (AJK, JC, OKD); statistical analysis (WTD); obtaining funding (JAS, AJK); administrative, technical, or logistic support (JC); and supervision (JAS).

Address correspondence to: Julie A. Schmittdiel, PhD, Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612. E-mail: Julie.A.Schmittdiel@kp.org
1. Medel M; for the Pharmaceutical Strategies Group. PBM 101. http:// www.psgconsults.com/resources/pbm_101.pdf. Published 2011. Accessed June 24, 2011.

2. Federal Trade Commission. Pharmacy Benefit Managers: Ownership of Mail-Order Pharmacies. Washington, DC: Federal Trade Commission; 2005.

3. Duru OK, Schmittdiel J, Dyer W, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010;16(1):33-40.

4. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent health care utilization and cost. Am J Manag Care. 2010;16(8):568-576.

5. Devine S, Vlahiotis A, Sundar H. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy. J Med Econ. 2010;13(2):203-211.

6. Zhang L, Zakharyan A, Stockl KM, Harada AS, Curtis BS, Solow BK. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ. 2011;14(5):562-567.

7. Schmittdiel J, Karter A, Dyer W, et al. The comparative effectiveness of mail order pharmacy vs. local pharmacy use on LDL-C control in new statin users. J Gen Intern Med. 2011;26(12):1396-1402.

8. Duru OK, Gerzoff RB, Selby JV, et al. Identifying risk factors for racial disparities in diabetes outcomes: the Translating Research Into Action for Diabetes Study. Med Care. 2009;47(6):700-706.

9. Parchman ML, Culler SD. Preventable hospitalizations in primary care shortage areas: an analysis of vulnerable Medicare beneficiaries. Arch Fam Med. 1999;8(6):487-491.

10. Ballard DW, Price M, Fung V, et al. Validation of an algorithm for categorizing the severity of hospital emergency department visits. Med Care. 2010;48(1):58-63.

11. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium.” JAMA. 2010;304(14): 1592-1601.

12. Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectrum. 2002;15(4):240-248.

13. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med. 2005;20(2):1120-1126.

14. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population [published correction appears in JAMA. 2002;288(1):46]. JAMA. 2002;287(19):2519-2527.

15. Kruzikas DT, Jiang HJ, Remus D, et al. Preventable Hospitalizations: A Window Into Primary and Preventive Care, 2000. HCUP Fact Book No. 5. AHRQ Publication No. 04-0056. Agency for Healthcare Research and Quality. http://archive.ahrq.gov/data/hcup/factbk5/. Published September 2004. Accessed December 5, 2011.

16. Moffet HH, Parker MM, SkarKare U, et al. Adherence to laboratory test requests by patients with diabetes: the Diabetes Study of Northern California (DISTANCE). Am J Manag Care. 2011;17(5):339-344.

17. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (2003). 2004;44(2):142-151.

18. Messer LC, Laraia BA, Kaufman JS, et al. The development of a standardized neighborhood deprivation index. J Urban Health; 83(6): 1041-1062.

19. Laraia B, Karter AJ, Warton RM, Schillinger D, Moffet HH, Adler N. Place matters: neighborhood deprivation and cardiometabolic risk factors in the Diabetes Study of Northern California (DISTANCE). Soc Sci Med. 2012;74(7):1082-1090.

20. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.

21. Rosenbaum PR. Discussion hidden bias in observational studies. Ann Intern Med. 1991;115(11):901-905.

22. Chang VW, Hillier AE, Mehta NK. Neighborhood racial isolation, disorder and obesity. Soc Forces. 2009;87(4):2063-2092.

23. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalizations and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.

24. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153.

25. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.

26. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of  adherence to new prescriptions. Health Serv Res. 2009;44(5, pt l): 1640-1661.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up